Steven Cohen Verve Therapeutics, Inc. Call Options Transaction History
Point72 Asset Management, L.P.
- $39.3 Billion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding VERV
# of Institutions
170Shares Held
78.3MCall Options Held
125KPut Options Held
185K-
Alphabet Inc. Mountain View, CA12.3MShares$77.6 Million7.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.33MShares$39.8 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.04MShares$37.9 Million0.57% of portfolio
-
Black Rock Inc. New York, NY5.37MShares$33.7 Million0.0% of portfolio
-
State Street Corp Boston, MA5.1MShares$32 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $376M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...